Alan Levin

Actylis Corp. engages in the development, marketing, sale, and distribution of chemical compounds used in the pharmaceutical, nutraceutical, agricultural, coatings, and industrial chemical industries. It operates through the following segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment develops and sells finished dosage form generic drugs and nutraceutical products. The Pharmaceutical Ingredients segment supplies active pharmaceutical ingredients and pharmaceutical intermediates. The Performance Chemicals segment comprises of specialty chemicals and agricultural protection products. The company was founded in 1947 and is headquartered in Port Washington, NY.

Diffusion Pharmaceuticals LLC develops and manufactures pharmaceutical products. The firm develops trans sodium crocetinate for use in cancers types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. The company was founded by Matthew W. Hantzmon, John L. Gainer, and David G. Kalergis in February 2001 and is headquartered in Charlottesville, VA.

RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL.

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.

Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA.